首页> 外文期刊>International Journal of Biomedical Science >Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
【24h】

Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method

机译:在NSCLC中EML4-ALK融合基因的新型变异的鉴定:RT-PCR方法的潜在好处

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: The discovery of the transforming fusion gene of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein like 4 (EML4) as an oncogene in 2007 has led to its validation as a clinical target in NSCLC patients in a short period of time. The inhibition of the anaplastic lymphoma receptor tyrosine kinase has demonstrated to prolong progression-free survival compared to the standard of care chemotherapy in patients with advanced NSCLC that are ALK positive. However, the clinical implications of the 15 different variants of the EML4-ALK transforming gene described so far are currently not defined. Here we present a novel variant of the EML4-ALK fusion gene which we named variant 3c. Methods: RNA extracted from formalin fixed paraffin embedded (FFPE) specimens from patients with advanced and metastatic NSCLC was amplified, using primers and probes designed to detect specific EML4-ALK fusion gene fragments. Gel electrophoresis showed a different band for the new variant 3c compared to the known bands of positive cell lines for variant 3a and 3b. These findings were further investigated by dye-terminator Sequencing and FISH. Results: The novel variant, detected in two NSCLC specimens, is longer than v3a and shorter than v3b, representing an 18 base pair insertion of intron 19 of ALK between exon 6 of EML4 and exon 20 of ALK. All of the two samples showed exactly the same sequencing result. One of the samples was negative for FISH break apart testing and the other one showed a positive result, defined by≥15% split nuclei as indicative of an ALK rearrangement. Conclusions: Compared to FISH technology, RT-PCR enables the detection of different isoforms of the EML4-ALK transforming gene, which can be validated by sequencing. Only one out of two samples that were positive for the new variant by RT-PCR could be confirmed by FISH. The clinical significance of the different variants, notably to resistance and response to ALK-Inhibitors and the concordance and sensitivity of FISH and RT-PCR should be subject to further investigations.
机译:背景:间变性淋巴瘤激酶(ALK)的转化融合基因与棘皮动物微管相关蛋白如4(EML4)作为致癌基因的发现,使其在短期内成为NSCLC患者的临床靶标时间。与ALK阳性的晚期NSCLC患者的护理化疗标准相比,已证明,间变性淋巴瘤受体酪氨酸激酶的抑制可延长无进展生存期。但是,到目前为止,尚未描述迄今为止描述的EML4-ALK转化基因的15种不同变体的临床意义。在这里,我们介绍了EML4-ALK融合基因的新型变体,我们将其命名为变体3c。方法:使用设计用于检测特定EML4-ALK融合基因片段的引物和探针,扩增福尔马林固定石蜡包埋(FFPE)标本中晚期和转移性NSCLC患者的RNA。与变体3a和3b的阳性细胞系的已知条带相比,凝胶电泳显示新变体3c的条带不同。通过染料终止测序和FISH进一步研究了这些发现。结果:在两个NSCLC标本中检测到的新变异体比v3a长,比v3b短,代表ALK内含子19在EML4的6号外显子和ALK的20号外显子之间插入了18个碱基对。两个样品都显示出完全相同的测序结果。其中一个样品的FISH裂解试验阴性,另一个样品显示阳性结果,由≥15%的分裂核定义为ALK重排。结论:与FISH技术相比,RT-PCR能够检测EML4-ALK转化基因的不同同工型,可通过测序进行验证。 FISH可以确认RT-PCR对新变体呈阳性的两个样本中只有一个。不同变体的临床意义,尤其是对ALK抑制剂的耐药性和应答以及FISH和RT-PCR的一致性和敏感性,应进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号